Supraventricular tachycardia in neonates: antiarrhythmic drug choice dilemma

Abstract

Supraventricular tachycardia (SVT), being atrioventricular re-entry the underlying mechanism, is the most frequent tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.

Keywords:

• Tachycardia
• neonates
• antiarrhythmic drug
• treatment
• prophylaxis

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.